Personalis provides genetic tests for cancer. Co. also provides sequencing and data analysis services to support population sequencing initiatives. Co. operates and manages its business as one reportable operating segment, which is the sale of sequencing and data analysis services. Co.'s products include NeXT Platform, which is a platform that enable the analysis of both a tumor and its microenvironment from a single sample. Co. has created an ecosystem of products and capabilities built on the NeXT Platform: ImmunoID Next (tumor profiling from tissue), NeXT Liquid Biopsy (tumor profiling from plasma) and NeXT Personal (liquid biopsy providing for personalized tumor tracking for patients). The PSNL average annual return since 2019 is shown above.
The Average Annual Return on the PSNL average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PSNL average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PSNL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|